| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Sep, 2024 |
| Sales | 0 | 20 | 50 | 0 | 1,220 |
| Sales Growth | -100.00% | -60.00% | unch | -100.00% | unch |
| Net Income | -15,110 | -17,200 | -12,900 | -10,270 | -12,880 |
| Net Income Growth | +12.15% | -33.33% | -25.61% | +20.26% | -48.22% |
Connect Biopharma Holdings Ltd ADR (CNTB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. The company's product candidate includes CBP-201. Connect Biopharma Holdings Limited is based in TAICANG, China.
Fiscal Year End Date: 12/31